Pharmacology
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Tezepelumab found to reduce oral corticosteroid use in severe asthma
The WAYFINDER study shows a clinically meaningful reduction in oral corticosteroid dosing, which may allow patients to get off steroids, said pulmonology expert Stephen T. Doyle, DO, MBA, FCCP.
-
Varenicline found effective for nicotine vaping cessation in youth
Researcher A. Eden Evins, MD, said she was surprised by the ineffectiveness of behavioral therapy alone.
-
Oseltamivir beats supportive care for patients hospitalized with seasonal influenza
Investigator Anthony Bai, MD, MSc, and infectious disease expert Christina Thornton, MD, PhD, discuss a large analysis that showed an in-hospital mortality rate of 3.5% for oseltamivir vs 4.9% for supportive care.
-
ORCA-3 replicates strong tobacco cessation results for cytisinicline
The ORCA-3 trial demonstrated that cytisinicline, a reformulated compound, significantly outperformed placebo by nearly six times in helping adults who smoke to quit.
-
Study shows earlier vasopressin initiation for sepsis reduced in-hospital mortality
Critical care expert Natalie Achamallah, MD, FCCP, said OVISS data support guidelines that recommend earlier vasopressin as well as lower norepinephrine doses.
-
UK trial finds propofol remains preferred ICU sedation agent
The recent A2B trial found that neither dexmedetomidine nor clonidine are superior to propofol and may increase risks of agitation and bradycardia.
-
As-needed albuterol-budesonide found to benefit mild asthma
Study author Craig LaForce, MD, and pulmonologist Kevin Fussell, MD, discuss findings from the BATURA trial and their clinical implications.
-
Ketamine vs etomidate for intubation in patients who are critically ill
Commonly used for sedation for endotracheal intubation, these drugs are often selected for their favorable hemodynamic profiles.
